Pfizer buys stake in French gene therapy firm Vivet

(Reuters) - Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease. Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8 million in clinical, regulatory milestone payments and to exercise the option to buy the whole company.

Reuters March 21, 2019 00:05:34 IST
Pfizer buys stake in French gene therapy firm Vivet

Pfizer buys stake in French gene therapy firm Vivet

(Reuters) - Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8 million in clinical, regulatory milestone payments and to exercise the option to buy the whole company.

Pfizer already has collaboration agreements with gene therapy companies including Spark Therapeutics and Sangamo Therapeutics to target conditions like hemophilia and certain neurodegenerative disorders.

Pfizer is one of several large pharmaceutical companies that has done deals to try to tap the potential for gene therapies to dramatically improve or even cure disease. Analysts expect the companies to charge more than $1 million for these therapies.

Last month, Swiss drugmaker Roche AG agreed to buy Spark Therapeutics, which developed the only approved gene therapy on the U.S. market, for $4.3 billion.

The FDA is also expected to decide on whether to approve a gene therapy for spinal muscular atrophy from Novartis AG later this year.

In a joint statement on Wednesday, Vivet and Pfizer said Pfizer can exercise its option to acquire all of Vivet following its delivery of certain data from an early-stage clinical trial for its VTX-801, an experimental treatment for Wilson disease.

Wilson disease, which can be life-threatening, is a rare inherited disorder that causes copper to accumulate in the liver, brain and other vital organs.

(Reporting by Manojna Maddipatla in Bengaluru;' Editing by Shinjini Ganguli and Maju Samuel)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

Gold rebounds as U.S. non-farm payrolls fall short of expectations
Business

Gold rebounds as U.S. non-farm payrolls fall short of expectations

By Sumita Layek (Reuters) - Gold rebounded from a more than two-week low on Friday after U.S. nonfarm payrolls did not rise as much as expected, although bullion was still on course to register its biggest weekly decline since March

Euro zone retail sales fall more than expected in April
Business

Euro zone retail sales fall more than expected in April

BRUSSELS (Reuters) - Euro zone retail sales fell more than expected in April, dragged down by a decline in sales of non-food products, but were still much higher than 12 months earlier when most countries were under strict pandemic lockdowns, data showed on Friday. The European Union's statistics office Eurostat said retail sales in the 19 countries sharing the euro fell 3.1% month-on-month in April but were 23.9% higher than a year earlier

U.S. leisure and hospitality pay surges to a record. Now will workers come?
Business

U.S. leisure and hospitality pay surges to a record. Now will workers come?

By Jonnelle Marte and Ann Saphir (Reuters) - Hotels, restaurants and other businesses are boosting pay as they try to rebuild their staffs and meet increasing demand from Americans ready to venture out as pandemic-related restrictions are lifted and more people are vaccinated.